BURNABY, BC, June 19 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX- V: WBI), a biotechnology company developing therapeutic drugs for the treatment of anti-inflammatory and auto-immune diseases and cancer, is pleased to announce that the clinical component of a Phase IIa trial on Atopic Dermatitis (a form of eczema) has been completed. The final report on this randomized, double-blinded, vehicle-controlled study to evaluate the safety, tolerability and efficacy of topically applied WBI-1001 cream in subjects with Atopic Dermatitis (AD) is expected later this summer.

Atopic Dermatitis is a chronic, inflammatory condition that causes the skin to become inflamed, cracked and itchy. It occurs worldwide, its prevalence is increasing and in North America it affects over 15 million people. The condition is especially prevalent in young children. Current therapeutic treatments have variable efficacy and often undesirable side effects.

The Company has initiated plans for a Phase IIb clinical trial to further evaluate the properties of WBI-1001 as a topical cream application against AD.

ON BEHALF OF THE BOARD

York Yingping Guo

President and Chief Executive Officer

The TSX Venture Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of the content of this news

release. This press release contains forward-looking statements that

include our belief as to the potential of our products. Certain risks and

uncertainties such as our ability to successfully commercialize the

products could cause the Company's actual results to differ materially

from those in the forward-looking statements. The Company thus seeks safe

harbour.

%SEDAR: 00021386E